On January 14, 2021, days before a change in presidential administrations, the US Department of Health and Human Services (HHS) announced a plan to publish Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder “pursuant to 21 USC §823(g)(2)(H)(i)(II),” a provision of the Drug Addiction and Treatment Act of 2000 (DATA 2000).1 This announcement caused a mix of enthusiasm, skepticism, and confusion in the medical community, and the retraction of the plan to publish the guideline less than 2 weeks later by the Biden administration has created an opportunity for fundamental and needed reform.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Olsen Y, Fitzgerald RM, Wakeman SE. Overcoming Barriers to Treatment of Opioid Use Disorder. JAMA. 2021;325(12):1149–1150. doi:10.1001/jama.2021.1741
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: